×
TMDX is down -6.25% to about $71.74 during regular market hours, versus a prior-session close of $76.52. The drop reflects broad risk-off in high-multiple medical device names as the 10-year Treasury yield briefly topped 5% ahead of the Fed decision, pressuring growth stocks.
Heart and lung clinical catalysts: The next-generation OCS ENHANCE Heart trial and OCS DENOVO Lung trial represent the clearest near-term drivers of adoption and investor sentiment. Kidney opportunity ahead: Management has signaled a U.S. kidney program targeting an FDA (Food and Drug Administration) trial in early 2027, potentially expanding the addressable procedure base materially.
HUBC is a micro-cap cybersecurity firm undergoing major corporate restructuring, while MXCT is a cell-engineering technology provider with a cash-rich balance sheet. HUBC has experienced extreme price volatility tied to a reverse stock split and Nasdaq listing notices, whereas MXCT has shown steadier, though still negative, relative performance.
MaxCyte (MXCT) is a cell-engineering platform company, while Zhibao Technology (ZBAO) is a China-based InsurTech (insurance technology) firm, putting the two in entirely different sectors and risk profiles. MaxCyte reported lower 2025 revenue but maintains a large cash balance and a visible pipeline of cell-therapy licensing partners; Zhibao is growing revenue but remains unprofitable with a comparatively thin cash position.
Different life stages: BKHA is a special purpose acquisition company (SPAC) completing a merger, while MXCT is a commercial-stage cell-engineering platform with recurring revenue. Redemption signal: Holders of roughly 2.09 million BKHA Class A shares elected redemption ahead of its de-SPAC, taking out about $25.15 million and leaving only about $420,000 in the trust.
FBGL is a Singapore-based green building contractor, while MXCT is a U.S. cell-engineering technology company — two fundamentally different business models with little operational overlap. FBGL is a micro-cap stock with a highly concentrated float, low institutional ownership, and pronounced price volatility, trading well below its 52-week high.
MaxCyte ( MXCT ) is a U.S. cell-engineering company serving the cell and gene therapy sector, while WF Holding ( WFF ) is a Malaysia-based manufacturer of fiberglass reinforced plastic (FRP) industrial products. MXCT recently raised its full-year 2026 revenue guidance after stronger-than-expected preliminary third-quarter results, a clear positive catalyst.
BMEA is a pre-revenue, clinical-stage biopharmaceutical company, while MXCT is a revenue-generating cell-engineering tools provider with a stronger balance sheet. Both names are micro-cap life-science equities trading near the lower end of their 52-week ranges after sharp declines over the past year.
JBDI is a Singapore-based industrial container reconditioning business that recently announced a $900 million acquisition of an AI (artificial intelligence) social platform, triggering extreme share-price volatility. MXCT is a cell-engineering technology company serving the pharmaceutical and biotechnology industries, with a steadier, research-driven business model.
MXCT (MaxCyte, Inc.) is a cell-engineering technology company serving the biopharma and cell-therapy sectors, while NWGL (CL Workshop Group Limited, formerly Nature Wood Group) is a vertically integrated forestry and wood-products company. The two stocks operate in unrelated industries, making this a comparison of market positioning, financial strength, and relative performance rather than direct business competition.
MXCT (MaxCyte) is a cell-engineering company serving the biotech and cell-therapy market, while YFOR (YYForce) is an AI-enabled workforce-management and facility-services provider. MaxCyte recently raised its full-year revenue guidance after stronger-than-expected core revenue, while YYForce withdrew its fiscal-year outlook citing labor-cost pressure.
CDT is a clinical-stage biopharmaceutical company with limited cash and recurring operating losses, while MXCT is a cell-engineering platform business with a recurring-revenue model and a debt-free balance sheet. Both stocks operate in the healthcare sector but carry fundamentally different risk profiles: micro-cap CDT faces a going-concern warning, whereas MXCT holds over $140 million in cash and investments.
MXCT surged roughly +31.7% to about $1.27 from the prior close of $0.96, breaking higher after a multi-day decline. The gain began in premarket trading (up roughly +17%) and extended sharply during regular session hours.
Cytek Biosciences (CTKB) advanced roughly 15% over the trailing 30 days, rising from about $4.73 to $5.43 per share. The move was fueled by a clinical flow cytometry collaboration with Sysmex Europe, the launch of a new Cytek Cloud analysis tool, and renewed investor interest in life-sciences tools.
QSI shares surged +27.05% to roughly $1.55 during Thursday's regular session, up from a $1.22 prior close. The rally followed H.C. Wainwright reiterating a Buy rating and $4.00 price target on the stock.
ALGN is a large-cap, profitable medical device leader (Invisalign clear aligners and iTero scanners), while VVOS is a micro-cap, unprofitable sleep apnea device company in a strategic pivot. The two names differ sharply in scale, with Align Technology near a $10 billion market value and Vivos Therapeutics around a low-single-digit million-dollar market capitalization.
GKOS fell -11.58% to roughly $152.24 during regular session trading on Oct. 8, reversing the prior session's +6.55% advance. The slide deepened through the morning; the stock was already down about -7.4% earlier in the session.
GEHC is a large, profitable medical-technology franchise with roughly $29 billion in market value, while HYPR is a small, pre-profit growth company with a market value near $90 million. GEHC is expanding its high-growth radiopharmaceuticals business through a $945 million cash acquisition of SOFIE Biosciences, announced in recent weeks.
Proteus platform launch is the defining near-term catalyst, with commercial availability targeted for the end of 2026. Amino acid detection milestones are de-risking the platform, with 18 of 20 amino acids now detectable and all 20 targeted by year-end.
QSI is trading down -4.1% intraday during regular session, near $1.17 versus Friday's $1.22 close. The decline extends a multi-day pullback after last week's sharp speculative run-up on interim Proteus data presented at HUPO 2026.
Previous
24 of 31
Next